Changing trends in the use of novel oral anticoagulants and warfarin for treating non-valvular atrial fibrillation. (March 2020)

• Record Type: Journal Article
• Authors: Birkinshaw, Alexander; Fry, Christopher H; Fluck, David; Sharma, Pankaj; Han, Thang S
• Is Part Of: JRSM cardiovascular disease. Volume 9(2020)
• Publication Date: 2020-03
• Subjects: Pharmaco-economics -- thromboembolism -- vitamin K antagonists; Cardiovascular system -- Diseases -- Periodicals; 616.1005
• DOI: 10.1177/2048004020915406
• Languages: English
• ISSNs: 2048-0040

Abstract

Background: Prevention of thromboembolism by novel oral anticoagulants is increasing, whilst use of vitamin K antagonists is on the decline. We assessed changes in the use of these anticoagulants in treating non-valvular atrial fibrillation between 2014 and 2018. Methods: One-hundred and sixty-two consecutive patients (95 men, 67 women) with non-valvular atrial fibrillation, mean age 72.3 years (standard deviation = 11.0), underwent cardiac assessment in a single cardiac unit. Use of anticoagulants at the time of investigation was documented: overall 83 (51.2%) patients were prescribed novel oral anticoagulants and 79 (48.8%) warfarin treatment. Trends in treatment rates with either anticoagulant class over time were characterised by calculating the average annual percentage change using a Joinpoint Regression Program 4.7.0.0. Results: There were diverging trends in anticoagulant treatment from 2014 to 2018 without join points: yearly increase in novel oral anticoagulant treatment (41.9, 45.5, 53.7, 53.1 and 72.7%, average annual percentage change = 16.2%, 95% confidence interval = 5.8% to 27.5%, p < 0.001), and decrease in warfarin treatment (57.1, 54.5, 46.3, 46.9 and 27.3%, average annual percentage change = −14.4%, 95% confidence interval = −25.2% to −2.1%, p < 0.001). Conclusions: Changing trends in treatment with anticoagulants for patients with non-valvular atrial fibrillation observed within less than two years provide important information to healthcare services to estimate future pharmaco-economic costs for such treatments.